Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Biotechnology

Healthcare
$27.39 +1.67%

+$1.22 today

Market cap
$4.56B
Beta
0.37
P/E (TTM)
-37.5
EPS (TTM)
-$1.98
52W Low $36.45High $86.74

Volume 3.23M

Average 1.83M

IONS Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Ionis Pharmaceuticals, Inc.NASDAQ: IONS

Short-term Debt · Q3 FY2026 · quarter ended Sep 2026

Short-term debt falls 78.1% from a year ago

Short-term debt stood at $138.19M at the end of Q3 FY2026, down 78.1% from a year earlier and down 42.9% from the prior quarter. Over 3 fiscal years it compounded at +291.8% a year.

Context

  • Short-term debt amounted to 4.7% of total assets at the end of Q3 FY2026, down 16.1 pp from a year earlier.
  • Short-term debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term debt keeps falling in the next quarterly balance sheet after a -78.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$138.19M-42.9% QoQ
Last fiscal yearDec 2025
$453.15M+4783.6% YoY
Year agoSep 2025
$630.91M-78.1% since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-78.1%——
1 year+4783.6%——
3-year CAGR+291.8%——
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
453.15M USD
Year-over-year change
+4783.6%
4-year CAGR
+236.7%

Short-term Debt vs competitors

How IONS compares with its peers on the latest reported figures

  • IONS's Sep 2026 short-term debt of $138.19M is the 4th highest of the 9 companies compared; the peer median is $63.73M.
  • Its year-over-year change of -78.1% is the lowest of 2, against a peer median of +5611.4%.
  • Short-term debt amounts to 4.7% of total assets for IONS, versus a peer median of 2.1%.
IONS Competitors Peer median
Short-term Debt for IONS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMRNBioMarin Pharmaceutical Inc.Sep 2026$658.72B ——5.7%
BIIBBiogen Inc.Jun 2026$800M ——2.5%
BBIOBridgeBio Pharma, Inc.Jun 2026$547.96M +5611.4%—45.0%
IONSIonis Pharmaceuticals, Inc.Sep 2026$138.19M -78.1%+291.8%4.7%
RAREUltragenyx Pharmaceutical Inc.Mar 2026$72M ——5.6%
PTCTPTC Therapeutics, Inc.Jun 2026$55.45M —+99.1%1.7%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
SRPTSarepta Therapeutics, Inc.Mar 2026$0 ——0.0%
NTLAIntellia Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding IONS) $63.73M+5611.4%+99.1%2.1%

Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents869.19M276.47M399.27M242.08M372.26M
Short-term Investments1.26B1.72B1.93B2.06B2.31B
Net Receivables61.9M25.54M97.78M92.19M66M
Inventory24.81M22.03M7.44M12.51M10.05M
Other Current Assets125.17M157.72M205.43M217.93M247M
Total Current Assets2.35B2.2B2.64B2.62B2.99B
Property, Plant & Equipment (Net)196.04M255.84M242.94M256.11M362M
Goodwill00000
Intangible Assets29.01M0000
Long-term Investments32.32M40.37M42.99M41.02M52.21M
Tax Assets00000
Other Non-current Assets9.27M34.97M62.29M86.26M119.39M
Total Non-current Assets266.64M331.18M348.22M383.39M533.2M
Total Assets2.61B2.53B2.99B3B3.52B
Account Payables11.9M17.92M26.03M42.96M28.08M
Short-term Debt3.53M7.54M53.16M9.28M453.15M
Tax Payables36K6.25M2.15M34K0
Deferred Revenue97.71M90.58M151.13M78.99M73.76M
Other Current Liabilities38.81M49.18M67.73M69.61M107.63M
Total Current Liabilities240.55M311.56M448.09M309.32M781.57M
Long-term Debt1.23B1.18B1.23B1.25B1.9B
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)351.88M287.77M241.18M156.5M92M
Other Non-current Liabilities00513.74M542.21M0
Total Non-current Liabilities1.6B1.65B2.16B2.11B2.25B
Total Liabilities1.84B1.96B2.6B2.42B3.03B
Common Stock141K142K144K158K163K
Retained Earnings(1.16B)(1.43B)(1.8B)(2.25B)(2.63B)
Accumulated OCI(32.67M)(57.48M)(32.65M)(30.81M)(25.28M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity771.74M572.89M386.69M588.35M489.09M
Total Debt1.25B1.37B1.45B1.42B2.61B
Net Debt381.86M1.09B1.05B1.17B2.24B

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Intrinsic Alpha fair value

Locked

Current Price

$27.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.